REGENXBIO (NASDAQ:RGNX – Get Free Report) is set to announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The firm had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $22.97 million. During the same quarter last year, the company earned ($1.66) EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts expect REGENXBIO to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
REGENXBIO Stock Up 1.9 %
Shares of RGNX opened at $9.01 on Thursday. REGENXBIO has a 52-week low of $8.81 and a 52-week high of $28.80. The firm’s fifty day moving average is $10.98 and its two-hundred day moving average is $12.84. The stock has a market cap of $443.80 million, a PE ratio of -1.50 and a beta of 1.21.
Analyst Upgrades and Downgrades
Read Our Latest Report on REGENXBIO
Insider Activity at REGENXBIO
In related news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now directly owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.13% of the stock is owned by insiders.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
- Five stocks we like better than REGENXBIO
- Why Invest in 5G? How to Invest in 5G Stocks
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What is the S&P 500 and How It is Distinct from Other Indexes
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.